الصفحة الرئيسية>>Lipids>> Prostaglandins>>Tepoxalin

Tepoxalin (Synonyms: ORF 20485, RWJ 20485)

رقم الكتالوجGC49386

Tepoxalin هو مثبط مزدوج لـ COX و 5-lipoxygenase (5-LO) مع نشاط قوي مضاد للالتهابات وملف معدي معوي ملائم

Products are for research use only. Not for human use. We do not sell to patients.

Tepoxalin التركيب الكيميائي

Cas No.: 103475-41-8

الحجم السعر المخزون الكميّة
1 mg
31٫00
متوفر
5 mg
141٫00
متوفر
10 mg
204٫00
متوفر
25 mg
464٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Tepoxalin is a dual inhibitor of COX and 5-lipoxygenase (5-LO; IC50s = 2.84 and 0.15 µM, respectively, in RBL-1 cell lysates).1 It also inhibits the activity of 12-, but not 15-, LO (IC50s = 4.45 and 146.6 µM for the human platelet and rabbit reticulocyte enzymes, respectively). Tepoxalin reduces the production of thromboxane B2 and leukotriene B4 induced by the calcium ionophore A23187 in human peripheral blood mononuclear cells (PBMCs; IC50s = 0.01 and 0.07 µM, respectively) and decreases epinephrine-induced platelet aggregation in human platelet-rich plasma (PRP; IC50 = 0.045 µM). It inhibits paw swelling in a rat model of adjuvant-induced arthritis with an ED50 value of 3.5 mg/kg.

1.Argentieri, D.C., Ritchie, D.M., Ferro, M.P., et al.Tepoxalin: A dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profileJ. Pharmacol. Exp. Ther.271(3)1399-1408(1994)

مراجعات

Review for Tepoxalin

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tepoxalin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.